Gastric infections are mostly triggered by Helicobacter pylori (H. pylori), a fungus that colonizes the stomach mucosa of more than 50% of the i nhabitants of the world. Chronic H. Pylori diseasewas associated with stomach diseases such as peptic ulcer, chronic gastritis and stomach aden oc arcinoma. Current therapy for eradication relies on antibiotic-based therapies that are ineffective in about 20% of patients. Traditional method constraints optimize the creation of new techniques for fast, consistent and cost-effective H diagnosis. Infection with pylori. Wideranging study has been carried out over the previous few centuries to create a type of gastro-retentive dosage (GRDF). This sort of dosage form can advance the delivery and efficiency of stomach-active medicines because the GRDF enables the medication to remain in the stomach for a sufficient time period. Various methods were used to develop effective GRDFs such as high-density systems, low-density systems, swelling and expansion systems, hydrodynamically balanced systems, superporous hydrogels,. However, there are both merits and demerits in these kinds of schemes. Intra-individual and inter-individual dissimilarities are obstacles to the growth of effective GRDFs in gastric physiology. Examples of these individual differences include gastric pH and gastric motility that have a notable effect on the moment of stomach retention and delivery of drugs. Some of these obstacles can be overcome by developing a novel mucoadhesive microsphere. The mucoadhesive microsphere is characterized by close contact of the MDF with the mucosal layer, thereby increasing the localized absorption of the drug. H2Receptor antagonists (H2RAs) have become first-line therapy for acid related peptic disease and GRDF especially designed for H2RAs and drugs against H. pylori, including specific targeting systems and leading to a marked development in the quality of life for a large number of patients. In this relationship, new formulations with improved absorption, improved bioavailability and improved acid-suppressing regimens are welcome
Introduction
H. Pylori, a gram-negative microaerophilic spiral bacterium, were created in 1982 by Warren and Marshall as a significant cause organism for peptic ulcer 1 . Approximately half of the world's inhabitants are infected with this pathogen, but only a tiny percentage of infected inhabitants show clinical signs, mostly dependent on bacterial virulence dissimilarity and hostile factor. H. Pylori infection occurs in 90-100% of patients with duodenal ulcer and 60-90% of patients with stomach ulcer. The H has been shown by numerous researches. Pylori infection is associated with an enhanced danger of peptic ulcer disease of at least 3 to 4 folds and that of 10-15% H. Individuals infected with pylori will have the disease of peptic ulcer in their lifetime 2 . H. pylori is the major contributing organism of the unceasing gastritis 3 , peptic ulcer 4 , B-cell MALT lymphomas 5 , gastric carcinoma 6 , and childhood malnutrition-associated carcinoma 7 . All of these are associated with an increase in epithelial cell apoptosis 8 . WHO has programmed H. pylori-associated gastric carcinoma as one of the three major causes of cancer-related deaths universal, around 0.5 million deaths each year. Chemotherapy of gastric cancer has deprived clinical efficacy; however, the abolition of H. pylori infection could possibly stop gastric carcinoma and other associated diseases. It is now well recognized that the maximum incidence of H. pylori infection is additional in children of [11] [12] [13] [14] [15] [16] years mainly for lower socioeconomic condition due to deprived level of hygiene 9 . The occurrence of H. pylori infection in India has been reported to be extremely high, ranging from 70% to 90% in patients with duodenal and peptic ulcer and 50% to 80% in patients with non-ulcer dyspepsia as well as fit asymptomatic adults 10 . A triple therapy containing 2 antibiotics and 1 proton inhibitor over a period of 2 weeks is optional universal for abolition of H. pylori. But deprived stability of antibiotics in acidic environment and deprived permeation of antibiotics across the mucus layer cause incomplete abolition and systemic side effects leading to patient disobedience 11, 12 . Numerous study studies on gastro-retentive drug delivery systems such as floating formulations, mucoadhesive drug delivery system, pH-sensitive gel system were conducted in order to increase gastric residence and local drug concentration at H. pyloriinfected site. These studies indicated the advantage of targeting drug to the gastric mucosal layer by dropping the dose of antibiotic therapy as well as improved patient's compliance. In this review, we recapitulate the existing information on colonization of H. pylori and gastroretentive mucoadhesive microsphere studies conducted in past few years, so as to utilize the information for future research on H. pylori abolition therapy.
Colonization of H. pylori
H. pylori are a motile pathogen which lives profound in the gastric mucus layer close to the epithelial cells. In common, after the entrance of any bacteria into the stomach, gastric acidity and peristaltic movement slow down the bond and migration of the bacteria in the gastric mucus layer. The incessantly secreted mucus from glands of the epithelial cell pushes bacteria toward the luminal surface, where the extra acidic environment delays the colonization and motility property of the pathogens [13] [14] [15] . However, even in these aggressive conditions, H. pylori sticks to the mucus layer and penetrates deep in the mucus membrane close to the epithelial cells due to good motility of flagellae and various adhesions present on its surface as shown in Figure 1 . Once the bacterium establishes the adhesion with the mucus layer, the enzyme urease secreted by H. pylori metabolizes gastric urea to produce Co2 and ammonia, which produces a surrounding coat of buffered acid. previous it was assumed that H. pylori usually colonizes in the mucus just close nearby to epithelial cell and do not penetrate the epithelial cells 16 but one of the recent study showed the attack of H. pylori in the intercellular space of gastric epithelial cell 17 . Thus, migration of H. pylori in the gastric mucus layer is determined by various dangerous and aggressive factors. Urease and flagella are two most significant dangerous factors for successful migration of H. pylori 15, 18, 19 . Among aggressive factors, Lewis blood group antigens are most significant factors for mucosal adhesions of bacteria. Based on composition, Lewis antigen are of two types: type 1, mainly dispersed in the epithelium surface contain Lea, Leb and sialyl-Lea, while type 2 located deeper in the mucous/ parietal cell contain LeX, LeY and sialyl-LeX. It is also well recognized that Leb and LeX are major aggressive factors that are responsible for H. pylori adhesion to the gastric epithelial cell 20 . In addition to Lewis antigen, integrins are other factors for adhesion of H. pylori. Apart from lewis antigens, blood group antigen-binding adhesion (Bab A) protein 21 and Sialic acid-binding adhesion (Sab A) protein 22 are adhesion factors present on the outer membrane of H. pylori. Bab A and Sab A recognize hostile factors Leb and LeX respectively for adhesion on gastric epithelial cell 22, 23 . Sheu et al. (2003) 24 reported the expression of Leb antigen as a cause behind nearly 73% of H. pylori infection. Once H. pylori adheres to the epithelial cell, it produces a direct injurious effect, which is augmented by production and release of vacuolating cytotoxin (VacA) 25, 26 .
Figure 1: Steps involved in colonization of H. pylori

Present therapy and its limitations
The treatment chart presently adopted as a first-line option includes a combination of a proton pump inhibitor, amoxicillin and clarithromycin or metronidazole/tinidazole, according to International Guidelines 27,28 . This therapy continues during 7 to 14 days, twice a day. Abolition rates of H. pylori treated with a 14-day 3 therapy reached only 70% in non-ulcer dyspepsia patients and 80% in patients with peptic ulcer 27 . In Europe, Asia and North America rates of 20 to 45% have been reported 29 . This abolition rate is remote from the attractive rate to infectious diseases and from that proposed by the WHO 28, 30 . The major limitation of the present therapy results from the lack of therapeutic compliance, due to the occurrence of side effects and the uneasiness resulting from the multiple doses 31, 32 . These factors may lead to the expansion of antibiotic resistance 32 . Moreover, antimicrobial agents such as amoxicillin and clarithromycin are dishonored by gastric acid 30 . Therefore it is necessary to use higher doses, which is reflected in the increase of GIT side effects, namely diarrhea, nausea, vomiting, bloating and abdominal pain and as a result the discontinuation of the therapy 32 . Another important cause is the antibiotic resistance that H. pylori has been developing, for instance the resistance to metronidazole has reached around 40% in developed countries and exceeds 90% in developing countries 33 . The resistance to clarithromycin has also been increasing, reaching more than 20% in southern Europe 29 . The bacteria are sensitive to other antimicrobial drugs; nevertheless they cannot be used in acidic medium 30 . Not-withstanding, the antibiotic residence time in the stomach is inadequate to achieve significant concentrations capable of crossing the gastric mucosa and reaching the surface between the mucus gel layer and the epithelial cells, where the H. pylori resides. Although drug solutions reach the gastric luminal region, their absorption into deeper layers of the gastric mucosa is vulnerable by the mucous layer barrier 34 . In order to increase the efficacy of H. pylori abolition, different suggestions have been made, namely a bismuth-containing quadruple therapy, sequential and attendant treatment and the use of novel antibiotics, such as rifabutin 35, 36 . However, these options may have to take into account that the difficulty of the treatment plan, including the switch middle in the sequential treatment and the large number of pills in attendant and BCQ therapy, may decrease therapeutic compliance. To overcome these limitations, novel effective therapies have been proposed: probiotics 37,38 , phytomedicine, gastroretentive systems, namely floating drug delivery systems 39, 40 and in a preventive approach, the attempt to develop an effective vaccine 29 . One of the leading ISSN: 2250-1177
[682] CODEN (USA): JDDTAO promising therapies that have newly emerged is based on the use of micro-or nanoparticles for direct contact with the H. pylori, through drug delivery techniques or mucoadhesive properties.
Novel drug delivery approaches for H. pylori
Literature review reveals that local use of antibiotics to gastric mucosa resulted in better abolition compared to systemically available antibiotic 41 . Hence, for successful abolition of H. pylori the DDS should sufficiently deliver the therapeutic agent in the close nearness of the gastric mucus membrane. In current years, various novel approaches are used for increasing the gastric residence time of the delivery system and local action of the drug in stomach. Different strategies utilized are:
(i) Density-based approaches including a high density system and a low density system 
Physiological consideration
Over the past few decades, pharmaceutical study and formulation development scientists have documented the potential of site-specific ODDS. The stomach site has been recognized as a depot for CRDF. However, formulation scientists have to consider physiological variations such as gastric residence time, gastric emptying time and drug release from the dosage form. Once solid material (food and/or drug) is chewed and swallowed, the esophagus quickly transports it to the stomach. The stomach is mostly divided into two parts: the proximal stomach, consisting of the fundus and body and the distal stomach, consisting of the antrum (or pylorus). The proximal stomach serves as a food reservoir, whereas in the distal stomach the food is processed, forming chyme and proteins are partly broken down. The distal stomach (pylorus) acts as pump to help in GE. The rate of GE is prejudiced by both the volume of food and the composition of the gastric contents. However, the pattern of gastrointestinal motility varies significantly in both fasting and fed states, further influencing the GE time.
The fasted state is characterized by an interdigestive series of electrical events which cycle both through the stomach and small intestine every 2-3 h 42 . This cycling event is termed the migrating myoelectric complex (MMC). The MMC is classified into 4 phases 43 as enumerated below and as depicted in Fig. 2 . In the case of the fed state, the GE time is slowed as the onset of the MMC is interrupted. For example, the feeding state results in a lag time (i.e. 30 min-4 h) prior to the onset of GE.
Fig. 2. Motility pattern in GIT
Composition of gastric mucus
The stomach wall is composed of numerous distinct layers of tissue: outer mucosa, inner submucosa, muscularis externa and serosa. The mucosa or lining of the stomach is comprised of columnar epithelial tissue, lamina propria (composed of areolar connective tissue) and a thin layer of smooth muscle. The mucosal cells (goblet cells) exude mucus (a translucent and glutinous secretion) which coats the stomach lining and stops its destruction from the gastric juice 43 . The mean thickness of the mucosal layer varies from about 50 to 450 mm in humans. Mucus is a complex mixture and its composition varies depending upon the source and the pathological state of the human 44, 45 (Table 1) . Table 1 Composition of mucus 44, 45 .
Composition Percentage (%)
Water 90-95% 
Mucoadhesive microspheres
Recent advances in polymer science and drug carrier technologies have promulgated the development of novel drug carriers such as mucoadhesive microspheres that have boosted the use of bioadhesion in the drug delivery 46 . Mucoadhesive microspheres include microparticles and microcapsules of 1 to 1000 μm in diameter consisting either completely of mucoadhesive polymer or having an outer coating with adhesive property 47 . Microspheres have the possible to be used for controlled as well as spatial drug delivery. Incorporating mucoadhesivenes to microspheres leads to competent absorption and enhanced bioavailability of drug. Precise targeting of drug to the absorption site is achieved by using homing devices (ligand) like plant lactin,
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[683] CODEN (USA): JDDTAO bacterial adhesion etc. on the surface of the microspheres. Mucoadhesive microspheres can be modified to stick to mucosal linings of GIT, thus offering the possibilities of localized as well as systemic absorption of drug in controlled manner 48, 49 .
Mechanism of mucoadhesion
Usually, mucoadhesion occurs from the interactions between the drug and carrier molecules with different mucus membranes in two steps: the contact stage and the consolidation stage (Fig. 3) 50 . However, the mechanism of mucoadhesion is highly complex and not yet fully understood. Different chemical interactions such as ionic bonds, covalent bonds, hydrogen bonds, Van der Waals forces and hydrophobic interactions are concerned in the mucoadhesion process that facilitates interactions of drug molecules across the interface. Several theories have been investigated to allow the understanding of mucoadhesion 51 .
Electronic theory
Adsorption theory
Wetting theory
Diffusion theory
Fracture theory Fig. 3 The two stages in mucoadhesion
Types of Mucoadhesive Polymers
First generation mucoadhesive polymers
It may be divided into 3 main sub-categories, namely: Anionic polymers, Cationic polymers and non-ionic polymers. Amongst these anionic and cationic polymers have been exhibits the greatest mucoadhesive strength 52 .
Anionic polymers
Anionic polymers are the most widely employed mucoadhesive polymers within pharmaceutical formulation due to their high mucoadhesive functionality and low toxicity. These include alginates, carrageenan, poly acrylic acid and its weakly cross-linked derivatives and sodium carboxymethylcellulose. PAA and NaCMC possess excellent mucoadhesive characteristics due to the formation of strong hydrogen bonding interactions with mucin 53 . Polycarbophil and carbomer (Carbopol, PAA derivatives have been studied extensively as mucoadhesive platforms for drug delivery to the GI tract 54, 55 . Carbomers are cross-linked with allyl sucrose or allylpentaerythritol whereas polycarbophil polymers are cross-linked with divinyl glycol. Both compounds have the same acrylic backbone but vary in their cross-link density that is often tailored to suit pharmaceutical or cosmetic performance.
Cationic polymers
Chitosan is a cationic polysaccharide the most abundant polysaccharide in the planet, next to cellulose 56 . The most explored mucoadhesive polymers, chitosan is gaining increasing importance due to its good biocompatibility, biodegradability and due to their favourable toxicological 57 .The linearity of chitosan molecules also ensures sufficient chain flexibility for interpenetration 58 . Chitosan may provide improved drug delivery via mucoadhesive mechanism; it has also been shown to improve drug absorption via the paracellular route through neutralization of fixed anionic sites within the tight junctions between mucosal cells 59, 60 .
Novel second-generation mucoadhesives polymers.
Second generation includes lectins and thiolated polymers.
Lectin is normally defined as proteins or glycoprotein complexes of non-immune origin that are able to bind sugars selectively in a non-covalent manner 61 . Lectins are capable of attaching themselves to carbohydrates on the mucus or epithelial cell surface and have been extensively studied, especially for drug-targeting applications 62, 63 . These secondgeneration bioadhesives not only provide for cellular binding, but also for subsequent endo-and transcytosis.
Thiolated polymers, also designated thiomers, are hydrophilic macromolecules exhibiting free thiol groups on the polymeric backbone. Due to these functional groups, various features of polyacrylates and cellulose derivatives were strongly improved 64 . The presence of thiol groups in the polymer allows the formation of stable covalents bonds with cysteine-rich subdomains of mucus glycoproteins leading to increased residence time and improved bioavailability 65 . Other advantageous mucoadhesive properties of thiolated polymers include improved tensile strength, rapid swelling and water uptake behavior. .e.gvarious thiolated polymers include chitosan-thioglycolic acid,chitosan-thioethylamidine, alginate-cysteine.  Spray drying and spray congealing method.
Methods of Preparation of Mucoadhesive Microspheres
 Solvent removal method.
 Hot melt method.
 Polymerization
Conclusion
In gastric ulcers caused by H. pylori, the treatment requires high concentration of antibacterial agents like clarithromycin or metronidazole or amoxicillin in stomach and absorption through gastric mucosa. However, presently available conventional drug deliveries of these drugs fail to achieve the same. A lot of extraordinary novel drug delivery approaches making use of buoyancy and bioadhesion to increase the gastro-retention time have been developed for the treatment of H. pylori infection. Among many novel delivery systems investigated so far for gastric delivery of drugs for H. pylori, the mucoadhesive microspheres showed the great potential for the selectively delivering the drug at infection site. By modifying the surface groups present on mucoadhesive polymers, increased mobility of nanoparticles in the gastric mucus can be obtained for better abolition of H. pylori. These systems are connected with major problems like stability on prolonged storage, consistency of drug entrapment and drug release and industrial scale up. 
